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Abstract
Several data indicate that migraine, especially migraine with aura, is associated with an increased risk of ischemic
stroke and other vascular events. Of concern is whether the risk of ischemic stroke in migraineurs is magnified by
the use of hormonal contraceptives. As migraine prevalence is high in women of reproductive age, it is common to
face the issue of migraine and hormonal contraceptive use in clinical practice. In this document, we systematically
reviewed data about the association between migraine, ischemic stroke and hormonal contraceptive use. Thereafter
a consensus procedure among international experts was done to develop statements to support clinical decision
making, in terms of cardiovascular safety, for prescription of hormonal contraceptives to women with migraine.
Overall, quality of current evidence regarding the risk of ischemic stroke in migraineurs associated with the use of
hormonal contraceptives is low. Available data suggest that combined hormonal contraceptive may further increase
the risk of ischemic stroke in those who have migraine, specifically migraine with aura. Thus, our current statements
privilege safety and provide several suggestions to try to avoid possible risks. As the quality of available data is poor
further research is needed on this topic to increase safe use of hormonal contraceptives in women with migraine.
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Several case-control and cohort studies, as well as
pooled data analyses, indicate that migraine is a risk fac-
tor for stroke and other vascular events [1–6]. Most of
the evidence supports an increased risk of ischemic
stroke associated with migraine with aura [7–18]. For
migraine without aura, the interpretation of available
data is more complex as some studies reported that mi-
graine without aura is also associated with an increased
risk of ischemic stroke [10, 18, 19] whereas in others the
association was not confirmed [7, 11, 15, 16]. Further,
the definition of a clear association between migraine
without aura and ischemic stroke is even more complex
as some studies did not include information on migraine
aura [2, 18, 20, 21] and because of the challenge of aura
diagnosis in epidemiological studies. Two meta-analyses
did not demonstrate an association between migraine
without aura and ischemic stroke [5, 6]. Whether the
risk of ischemic stroke in women with migraine is mag-
nified by use of combined hormonal contraceptives
(HCs) is unclear. As migraine prevalence is high in
women of reproductive age it is common to face the
issue of migraine and HC use in clinical practice [22].
Hence, the aim of the present paper is to systematically
review the association between migraine, ischemic stroke
and HC use and to develop a consensus among inter-
national experts to support clinical decision-making in
terms of cardiovascular safety for prescription by health-
care professionals of HCs to women with migraine.
Methods
In July 2016, European Headache Federation (EHF) rep-
resentatives selected a panel of international multidiscip-
linary experts in migraine, cardiovascular risks and
hormonal contraception. The panel was chosen to repre-
sent the breadth of knowledge and experience and a
wide variety of opinions internationally. The focus of
this statement is to provide guidance for clinicians. From
the original selected panel, two out of 17 members who
initially agreed to participate decided to leave the group,
and they are not included among the Panel members.
Review of the literature
A systematic search of the literature was conducted to
identify key papers addressing the association between
migraine and cardiovascular events in women using
HCs. An initial literature search included all papers
indexed on PubMed and Scopus, from inception to Au-
gust 30, 2016. The following search terms were used in
both databases: “migraine” AND (contraceptive OR es-
trogen) AND (vascular OR stroke OR “myocardial in-
farction” OR angina OR “coronary artery disease” OR
“coronary heart disease” OR “venous thrombosis”). Both
observational (cross-sectional, case-control, and cohort)
and intervention studies (RCTs) were included.
Two investigators from the statement Supporting
Group (FP and RO) independently screened the titles
and abstracts of the publications identified to verify
study eligibility. Full texts of selected studies were evalu-
ated when appropriate. Disagreements were resolved by
consensus. The reference lists and Google Scholar cita-
tions of the selected articles were also screened. To
summarize the search results, a data extraction sheet
was developed including the information of interest. A
formal systematic review of the association between mi-
graine and cardiovascular events and HCs as well as the
risk of vascular events was not performed and is avail-
able elsewhere [3–6, 23–26].
Papers retrieved from the literature search as well as
summary Tables were shared among the panelists before
starting the consensus procedure. The systematic litera-
ture search was repeated at the end of the consensus
procedure to include all relevant papers published until
March 30, 2017.
Development of the expert consensus
The consensus process incorporates a modified Delphi
method [27]. The Delphi method is largely used in the
healthcare setting as a reliable means of determining
consensus for a defined clinical problem [28–30]. This
method is an iterative process that uses a systematic
progression of repeated rounds of voting and is an ef-
fective process for determining expert group consensus
where there is little or no definitive evidence and where
opinion is important.
Development of the consensus statement was orga-
nized in four rounds. In each round, panelists were
instructed not to discuss among themselves and to send
their feedbacks only to the facilitator (SS). Two core
panelists (SS, PM) developed a draft document contain-
ing the list of items to be included in the statements
based on available literature and on clinical grounds.
The items were constructed as open-ended questions
and the document was used for soliciting information
from the panelists. In round 1, the draft containing the
questions was sent by e-mail to all panelists accompan-
ied by a clear explanation of the objectives of the study
and specific instructions. Panelists were asked to provide
free-text responses for each of the open questions and to
suggest additional items of relevance as warranted.
Thereafter, the facilitator analysed answers obtained dur-
ing round 1 and drafted the statements. In round 2, the
draft of the statements was sent by e-mail to all panel-
ists. Each panelist was asked to rate their agreement for
each statement by marking “completely agree”, “partly
agree (modifications required)” or “disagree” beside each
statement. Where panelists selected “partly agree” or
“disagree” for a statement, they were asked to provide a
free-text explanation for their selection. Panelists were
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also given the opportunity to provide comments and
suggestions and to identify further additional items not
included in the initial list of statements. Responses were
then analysed by the facilitator and used to refine state-
ments. In round 3, a revised draft was developed and
emailed to all panelists and the panelists were asked
again to vote their agreement, as in round 2, but with
the knowledge of the group scores and comments. Thus,
participants could reflect upon the group results and
change their mind, while preserving the anonymity of
their responses. Final responses were then analysed and
statements further refined. In round 4, a final draft of
the statements was e-mailed to all panelists. Panelists
were asked to simply express agreement or disagreement
for each statement without further comments. The pan-
elists were also required to provide a rank order of the
statements. Response frequencies for each item were cal-
culated and entered anonymously into a database. State-
ments to be included in the final document required
80% agreement from the panel [31].
Drafting of the statements
Quality of evidence and strength of the recommendations
were rated according to the American College of Chest
Physicians (ACCP) Task Force (Table 1) [32]. We also used
the suggestions provided by the ACCP referring to wording
of the recommendations. When making a strong recom-
mendation we used the terminology “We recommend…”
whereas when making a weak recommendation, less defini-
tive wording was used, such as, “We suggest…” was used.
Results
Systematic review
The systematic review of the literature identified six
studies that evaluated if HC use increased the risk of
stroke (ischemic, hemorrhagic, or both) in women with
migraine [10, 11, 17, 18, 33, 34]: four studies that evalu-
ated if the association between migraine and cardiovas-
cular diseases was modified by HC use [2, 35–37], and
two studies that reported descriptive information about
HC use and occurrence of stroke in women with mi-
graine [38, 39] Fig. 1.
Characteristics of the original research studies included
in the systematic review are reported in Table 2. All the
studies reporting stroke risk in women with migraine ac-
cording to HC use had a cross-sectional design and were
case-control and hospital-based [11, 17, 18, 33, 34] with the
exception of one population-based study [10]; two of the
studies reporting interaction by HC use had a prospective
or retrospective cohort design [2, 35] while other two stud-
ies had a case-control design [36, 37]; the two studies
reporting descriptive statistics had a cross-sectional
hospital-based design [38, 39]. HCs used in the selected
studies included pills containing ≥50 μg estrogen, 30–40 μg
estrogen, 20 μg estrogen, or progestogen only; seven studies
did not specify the type of HC [2, 10, 17, 35, 37–39].
The results of studies addressing the relationship among
migraine, HC use, and ischemic stroke are summarized in
Table 3. A case-control study showed that the risk of is-
chemic stroke was increased by 2-fold in migraineurs who
were HC users (odds ratio [OR] 2.1; 95% CI 1.2–3.7) as
Table 1 Grading recommendations according to the American College of Chest Physicians (ACCP) Task Force
Grade of Recommendation/
Description
Benefit vs Risk and Burdens Methodological Quality of Supporting
Evidence
Implications
1A/strong
recommendation,
high-quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs without important limitations or
overwhelming evidence from
observational studies
Strong recommendation, can apply to
most patients in most circumstances
without reservation
1B/strong
recommendation,
moderate quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
RCTs with important limitations
(inconsistent results, methodological flaws,
indirect, or imprecise) or exceptionally
strong evidence from observational studies
Strong recommendation, can apply to
most patients in most circumstances
without reservation
1C/strong
recommendation,
low-quality or very low
quality evidence
Benefits clearly outweigh risk
and burdens, or vice versa
Observational studies or case series Strong recommendation but may
change when higher quality evidence
becomes available
2A/weak recommendation,
high quality evidence
Benefits closely balanced with
risks and burden
RCTs without important limitations or
overwhelming evidence from observational
studies
Weak recommendation, best action
may differ depending on circumstances
or patients’ or societal values
2B/weak recommendation,
moderate-quality evidence
Benefits closely balanced with
risks and burden
RCTs with important limitations (inconsistent
results, methodological flaws, indirect, or
imprecise) or exceptionally strong evidence
from observational studies
Weak recommendation, best action may
differ depending on circumstances or
patients’ or societal values
2C/weak recommendation,
low quality or very
low-quality evidence
Uncertainty in the estimates
of benefits, risks, and burden;
benefits, risk, and burden may
be closely balanced
Observational studies or case series Very weak recommendations; other
alternatives may be equally reasonable
From Baumann MH et al. Chest 2001;119:590–602; RCT indicates randomized controlled trial
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compared to women with migraine who were HC non-
users [34], while another case-control study found a 7-fold
higher risk of ischemic stroke (OR 7.0; 95% CI 1.4–22.8)
in smokers and HC users compared with non-smokers
and non-HC users among women with migraine with aura
[17]. An early case-control study comparing women with
stroke versus stroke-free female control subjects showed
that the risk was increased by 5- to 6-fold in women with
migraine who were HC users (relative risk [RR] 4.6; 95%
confidence interval [CI] 2.2–9.6 for hospital controls
and 5.9; 2.9–12.2 for neighbor controls) and by 2-fold
in women with migraine who were HC non-users (RR
2.0; 95% 1.2–3.3; comparison to neighbor controls) as
compared to women without migraine [33]. A subse-
quent case-control study showed that the risk was in-
creased by 14-fold in women with migraine who were
HC users (odds ratio [OR] 13.9; 95% CI 5.5–35.1)
and by 4-fold in women with migraine who were HC
non-users (OR 3.7; 95% CI 1.5–9.1) as compared to
women without migraine who were HC non-users [18]. A
further case-control study showed that the risk was in-
creased by 17-fold in women with migraine who were HC
users (OR 16.9; 95% CI 2.7–106) but was unable to dem-
onstrate an association in women with migraine who were
HC non-users as compared to women without migraine
who were HC non-users [11]. Three case-control studies
Fig. 1 Flow-chart for the systematic review
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investigated the interaction among migraine, HC use, and
smoking in the determination of the risk of ischemic
stroke [11, 17, 36]; the first study found an adjusted OR
for ischemic stroke in migraineurs of 2.8 (P < 0.01; CI not
reported), in the absence of synergism between migraine,
HC use, and smoking [36]; another study found an OR of
34.4 (95% CI 3.27–361) for ischemic stroke in women
with migraine who used HC and smoked compared with
women without migraine, non-HC users, and non-
smokers [11]; the other study found an OR for ischemic
Table 3 Risk of ischemic stroke in subjects with migraine according to use of hormonal contraceptives
Study Population Comparison Odds ratio
(95% confidence interval)
Adjustment factors
Any migraine
Collaborative Group,
1975 [33]
Women with stroke,
hospital controls
Women with migraine and HC
use vs non-migraineurs, non-HC
users
4.6 (2.2–9.6)* Age
Women with stroke,
neighbor controls
Women with migraine and HC
use vs non-migraineurs, non-HC
users
4.6 (2.2–9.6)* Age
Lidegaard 1995 [36] Women with
ischemic stroke,
controls
Smokers, HC users, and migraineurs
vs non-smokers, non-HC users, and
non-migraineurs
3.3 (P < 0.01) HC, diabetes, arterial
hypertension, other
diseases
Tzourio, 1995 [18] Women with stroke,
controls
Women with migraine and HC use
vs non-migraineurs, non-HC users
13.9 (5.5–35.1) Not reported
Schwartz, 1998 [34] Women with
migraine
HC users vs non-HC users 2.1 (1.2–3.7) Age, smoking, body mass
index
Chang, 1999 [11] Women with stroke,
controls
Women with migraine and HC use
vs non-migraineurs, non-HC users
16.9 (2.7–106) Hypertension, education,
smoking, family history of
migraine, alcohol use, social
class
Women with stroke,
controls
Women with migraine, smoke, and
HC use vs non-migraineurs,
non-smokers, and non-HC users
34.4 (3.3–361) Not reported
Milhaud, 2001 [38] Women with
ischemic stroke
Women with migraine and HC use
vs non-migraineurs, non-HC users
2.7 (1.2–6.0) Not reported
Migraine with aura
MacClellan, 2007 [17] Women with
migraine with aura
Smokers and HC users vs non-smokers
and non-HC users
7.0 (1.4–22.8) Age, race, geographic region,
study period
Women with stroke,
controls
Women with migraine with aura,
smokers, and HC users, vs
non-migraineurs, non-smokers, and
non-HC users
10.0 (1.4–73.7) Age, race, geographic region,
study period
Champaloux, 2017 [10] Women with stroke,
controls
Women with migraine with aura and HC
users vs non-migraineurs and HC users
6.1 (3.1–12.1) Hypertension, diabetes,
obesity, smoking, ischemic
heart disease, valvular heart
disease
Women with stroke,
controls
Women with migraine with aura and
non-HC users vs non-migraineurs and
non-HC users
2.7 (1.9–3.7) Hypertension, diabetes,
obesity, smoking, ischemic
heart disease, valvular heart
disease
Migraine without aura
Champaloux, 2017 [10] Women with stroke,
controls
Women with migraine without aura and
HC users vs non-migraineurs and HC users
1.8 (1.1–2.9) Hypertension, diabetes,
obesity, smoking, ischemic
heart disease, valvular heart
disease
Women with stroke,
controls
Women with migraine without aura and
non-HC users vs non-migraineurs and
non-HC users
2.2 (1.9–2.7) Hypertension, diabetes,
obesity, smoking, ischemic
heart disease, valvular heart
disease
*Relative risk; HC indicates hormonal contraceptives
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stroke of 10.0 (95% CI 1.4–73.7) when comparing women
with migraine with aura who used HC and smoked with
women without migraine who were non-HC users and
non-smokers [17]. Two studies were performed in young
subjects with ischemic stroke [38, 39]; the first study
found that HC use was similar in women with migraine
and in the referent group (45% vs 30%; P = 0.056) and, in
the logistic regression analysis, HC use was a risk factor
for migraine [38]. The other study found that in a cohort
of ischemic stroke patients, HC use was similar in women
with migraine (with and without aura) and in the referent
group (36.7% vs 33.3% vs 36.8%; P = 0.905) [39]. One
population-based, case-control study reported separate re-
sults for women with migraine with and without aura, and
for HC users and non-users; in that study, the combin-
ation of HC use and migraine with aura was associated
with an OR of 6.1 (95% CI 3.1–12.1) for ischemic stroke
in women aged 15–49 years and the combination of HC
use and migraine without aura was associated with an OR
of 1.8 (95% CI 1.1–2.9) in the same risk [10]. Three studies
reported the interaction between migraine and HC use in
the determination of the risk of ischemic stroke [2, 35,
37]; in the first study, an increased OR for ischemic stroke
was found in subjects with history of migraine compared
with women without migraine (2.3, 95% CI 1.0–5.2), and
in current HC users compared with non-users (2.3, 95%
CI 1.2–4.6), in the absence of a significant interaction be-
tween migraine and HC use [37]. Another study showed
an increased risk of major cardiovascular events and of
cardiovascular mortality in women with migraine as com-
pared to women without that was not modified by HC use
(P for interaction all ≥0.84) [2]. A further study assessed
the risk of any stroke (both ischemic and hemorrhagic)
among triptan users 25–50 years of age and found a haz-
ard ratio (HR) of 1.4 (95% CI 1.3–1.7) which was not
changed after oral contraceptives were also adjusted for
[35]. However, whether the effect of triptan use on stroke
outcomes was modified by oral contraceptive was not
reported.
Risk of ischemic stroke associated with the use of
hormonal contraceptives
We calculated absolute risks of ischemic stroke in young
women according to migraine status and hormonal
contraceptive use (Table 4). Data were calculated consid-
ering an estimated incidence of ischemic stroke in
women aged 25 to 44 years of 2.5/100,000 [37]. For
migraine with aura we considered a pooled RR of ische-
mic stroke of 2.3 (95%CI 1.4–3.9, heterogeneity: Q = 8.3,
df = 3, p = 0.039, I2 = 64%) using a random effect model
meta-analysis by including the data from four studies
which provided the risk of ischemic stroke in women
with migraine with aura [11, 15, 17, 18]. We assumed no
interaction between HC use and migraine with aura on
the risk of ischemic stroke (P = 0.87) [17]. For migraine
without aura we considered a pooled RR of ischemic
stroke of 1.6 (95% CI 0.9–2.7, heterogeneity: Q = 8.05,
df = 3, p = 0.045, I2 = 63%) using a random effect model
meta-analysis by including the data from four studies
which provided the risk of ischemic stroke in women
with migraine without aura [11, 15, 17, 18]. We hypothe-
sized no interaction between HCs use and migraine
without aura in the risk of ischemic stroke (no data from
available articles).
The absolute risk of ischemic stroke among young
women who do not use HC is 2.5/100,000 per year
whereas the same risk among young women who use
HC is 6.3/100,000.
Considering women with migraine with aura, the risk
of ischemic stroke in those young women who do not
use HC is 5.9/100,000 per year whereas the same risk
among those young women who use HC is 36.9/100,000
per year.
Considering women with migraine without aura, the
risk of ischemic stroke in those young women who do
not use HC is 4.0/100,000 per year whereas the same
risk among those young women who use HC is 25.4/
100,000 per year.
Consensus statements
Statements are summarized in Table 5.
Statement 1: In women who are seeking hormonal
contraception, we recommend a clinical evaluation for
the presence of migraine, for the definition of migraine
subtype (i.e., with or without aura) and migraine fre-
quency together with the ascertainment of conventional
vascular risk factors before prescription of combined
hormonal contraceptives. 1C, Strong recommendation,
Low quality of evidence.
Comment: Women who are seeking HC should be
screened for the presence of vascular risk factors (i.e., ar-
terial hypertension, cigarette smoking, obesity, previous
history of cardiovascular disease, previous history of
deep vein thrombosis or pulmonary embolism) which
Table 4 Absolute risk of ischemic stroke in women aged 20 to 44 years in relation to the use of hormonal contraception and
migraine status
No migraine Migraine with aura Migraine without aura
Without hormonal contraception 2.5/100,000 5.9/100,000 4.0/100,000
With hormonal contraception 6.3/100,000 36.9/100,000 25.4/100,000
Data were calculated by using information provided in references #11,15,17,18,35
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may increase the risk of cardiovascular events including
ischemic stroke [40–42]. The Panel underscores the im-
portance of evaluating those women also for the pres-
ence of migraine and of the definition of migraine
subtypes (i.e., with or without aura). In fact, as detailed
in the systematic review, available data indicated an in-
creased risk of ischemic stroke in women with migraine
using HC [1, 5, 11, 18, 26, 33, 34] and for this reason the
presence of migraine deserves caution in prescription of
HCs as detailed in those Statements. However, there are
not enough data to address the risk of IS associated with
the use of HC according to migraine subtypes (i.e., with
or without aura) as most of the studies reported data for
overall migraine only. Only two studies reported the risk
of ischemic stroke in migraine with aura according to
HC use [10, 17]. In the earlier study, the risk of ischemic
Table 5 Statements with the strength of the recommendation and the quality of evidence
Statement Strength Quality of
evidence
1 In women who are seeking hormonal contraception, we recommend a clinical evaluation for the presence of migraine,
for the definition of migraine subtype (i.e., with or without aura) and migraine frequency together with the ascertainment
of conventional vascular risk factors before prescription of combined hormonal contraceptives
1, Strong C, Low
2 In women who are seeking hormonal contraception, we recommend the use of a dedicated, easy-to-use tool to
diagnose migraine and its subtypes (i.e., with and without aura)
1, Strong C, Low
3 In women who are seeking hormonal contraception, we recommend consideration of the type of hormonal
contraception taking into account their influence on the risk of ischemic stroke as there are high risk products (combined
oral contraceptives containing >35 μg ethinylestradiol), medium risk products (combined oral hormonal contraceptives
containing ≤35 μg ethinylestradiol, combined contraceptive patch, and combined vaginal ring) and no risk products
(progestogen-only contraceptives including oral pill, subdermal implant, depot-injection, and levonorgestrel-releasing
intrauterine system)
1, Strong B, Medium
4 In women with migraine with aura who are seeking hormonal contraception, we suggest against prescription of
combined hormonal contraceptives (oral pill, transdermal patch, and vaginal ring) containing ethinylestradiol and
17β-estradiol/estradiol valerate
2, Weak C, Low
5 In women with migraine with aura who are seeking contraception we suggest non-hormonal contraception
(condoms, copper-bearing intrauterine device, permanent methods) or progestogen-only contraceptives (oral pill,
subdermal implant, depot-injection, and levonorgestrel-releasing intrauterine system) as the preferential option
1, Strong C, Low
6 In women with migraine with aura who are already using combined hormonal contraceptives for contraception, we
suggest switching to non-hormonal contraception (condoms, copper-bearing intrauterine device, permanent methods) or
progestogen-only contraceptives (oral pill, subdermal implant, depot-injection, and levonorgestrel-releasing intrauterine
system)
2, Weak C, Low
7 In women with migraine without aura who are seeking hormonal contraception and who have additional risk factors
(cigarette smoking, arterial hypertension, obesity, previous history of cardiovascular disease, previous history of deep vein
thrombosis or pulmonary embolism), we suggest non-hormonal contraception (condoms, copper-bearing intrauterine
device, permanent methods) or progestogen-only contraceptives (oral pill, subdermal implant, depot-injection, and
levonorgestrel-releasing intrauterine system) as the preferential option
2, Weak C, Low
8 In women with migraine without aura who are seeking hormonal contraceptives and who have no additional risk factors
(cigarette smoking, arterial hypertension, obesity, previous history of cardiovascular disease, previous history of deep vein
thrombosis or pulmonary embolism) we suggest the use of combined hormonal contraceptives containing ≤35 μg dose
of ethinylestradiol as a possible contraceptive option with monitoring of migraine frequency and characteristics. Benefits
and risk of combined hormonal contraceptives use in comparison to other contraceptive options have to be balanced
carefully
2, Weak C, Low
9 In women with migraine with aura or migraine without aura who require hormonal treatment for polycystic ovary
syndrome or endometriosis we suggest to select the hormonal treatment of choice (progestogen-only or combined
hormonal contraceptives) on clinical grounds
2, Weak C, Low
10 In women who start combined hormonal contraceptives for contraception and who develop new onset of migraine with
aura, or who develop new onset migraine without aura in a temporal relationship to starting the hormonal contraceptive,
we suggest switching to non-hormonal contraception (condoms, copper-bearing intrauterine device, permanent
methods) or progestogen-only contraceptives (oral pill, subdermal implant, depot-injection, and levonorgestrel-releasing
intrauterine system).
2, Weak C, Low
11 In women with migraine with or without aura who require emergency contraception, we suggest the use of
levonorgestrel 1.5 mg orally, ulipristal acetate 30 mg orally, or the copper-bearing intrauterine device
2, Weak C, Low
12 In women with migraine with or without aura seeking hormonal contraception, we suggest against specific tests
(e.g. thrombophilia screening, patent foramen ovale evaluation or neuroimaging evaluation) to decide about
hormonal contraceptive prescription unless those tests are indicated by the patient’s history or by the presence of
specific symptoms
2, Weak C, Low
13 In women with non-migraine headache who are seeking hormonal contraception any low-dose hormonal
contraceptive can be used
2, Weak C, Low
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stroke in migraineurs with aura was similar among HC
users and nonusers, but the association among nonusers
attained statistical significance owing to a larger sample
size (OR, 1.5; 95% CI 1.1–2.1) [17]. In the more recent
study using a comparative group of women without mi-
graine and who were not using HCs as reference group,
authors found that women with migraine with aura and
active HC use had a 6-fold risk of ischemic stroke, while
the risk was lower (OR 2.7; 95% CI, 1.9–3.7) in women
with migraine with aura who were not using HCs [10].
In this same study authors reported evidence of an in-
creased risk of ischemic stroke in women with migraine
without aura either using (OR 1.8; 95% CI 1.1–2.9) or
not using HC (OR 2.2; 95% CI 1.9–2.7) as compared to
women without migraine and non-HC users. The study
did not formally test whether the effect of migraine (with
and without aura) on ischemic stroke was modified by
HC intake status. However, the Panel underscores that
definition of migraine subtype (i.e. with or without aura)
is important to understand better the possible increase
in the risk as several observational studies indicated that
migraine with aura is associated with an increased risk
of ischemic stroke [9–11, 13, 15, 17, 18, 43] while for
migraine without aura, the interpretation of available
data is more complex. In fact, some studies reported that
migraine without aura is associated with an increased
risk of ischemic stroke [10, 18, 19] whereas in others the
association seemed present but values did not reach stat-
istical significance [11, 15, 16].
The Panel suggests also to consider migraine fre-
quency in women who are seeking hormonal contracep-
tion. There are not enough data to establish if also low
migraine attack frequency (e.g. 4 attacks per year) is as-
sociated with the increased risk of ischemic stroke. How-
ever, migraine attack frequency for those with migraine
with aura appears to be an issue for determining the risk
of ischemic stroke. Findings from the World Health
Organization Collaborative Study of Cardiovascular Dis-
ease and Steroid Hormone Contraception indicated that
migraine with aura with migraine attacks more frequent
than 12 times per year (OR 10.4; 95% CI 2.2–49.4) was
associated with an increased risk of ischemic stroke [44].
Data from the Stroke Prevention in Young Women Study
indicated that women with migraine with aura with a
high migraine attack frequency (>12 attacks per year)
had higher odds of stroke (OR 1.7; 95% CI 1.1–2.8),
in addition to women with recent onset of migraine
with aura (OR 8.3; 95% CI 2.6–25.7) [17]. According
to data from the Women’s Health Study, the associ-
ation between migraine with aura and ischemic stroke
appeared J-shaped. Specifically, there were increased risks
for a migraine attack frequency of less than monthly (HR
1.9; 95% CI 1.2–3.1) and greater or equal to weekly (haz-
ard ratio [HR] 4.3; 95% CI 1.4–13.3), but not for monthly
migraine attacks [45]. Additionally, in this same cohort
there was evidence of the association between active
(within the last year) migraine with aura and ischemic
stroke whereas previous history of migraine was not asso-
ciated with ischemic stroke risk [45].
Statement 2: In women who are seeking hormonal
contraception, we recommend the use of a dedicated,
easy-to-use tool to diagnose migraine and its subtypes
(i.e., with and without aura). 1C, Strong recommenda-
tion, Low quality of evidence.
Comment: Migraine diagnosis is most reliable when
established by a headache specialist using the ICHD cri-
teria; however, a specialist diagnosis cannot be always
obtained in women seeking HC; in that clinical setting,
validated screening questionnaires may be useful to es-
tablish a headache diagnosis or to refer the appropriate
patients to headache specialists. Ideally, a screening
should initially assess whether women seeking HC suffer
from recurrent headaches, then whether recurrent head-
aches are migraine and, finally, whether migraine is with
or without aura. Types of migraine are not mutually ex-
clusive and around 30% of people with migraine with
aura also have attacks without aura [22, 46–48], with the
pattern changing over time.
Several migraine screening tools have been tested, includ-
ing two seminal questionnaires dating back to the 1990s
[49, 50], the Migraine Screen Questionnaire (MS-Q) [51],
the deCODE Migraine Questionnaire (DMQ3) [52], a
German questionnaire [53], and the Structured Migraine
Interview (SMI) [54]. ID-Migraine™ is a valid and reliable
symptom-based screener for migraine without aura that
has been developed for use in primary care [55]; the tool is
available also in other languages than English, including
Italian [56], Turkish [57], Portuguese [58], French [59], and
Chinese [60]. It is based on the three best predictors for
diagnosing migraine without aura, namely photophobia,
disability and nausea; patients who report two of these
symptoms have an 81% probability of having migraine and
three symptoms increases the probability to 93% (Table 6).
A sensitive and specific tool is the visual aura rating
scale (VARS) for migraine aura diagnosis, which is based
on the ICHD diagnostic criteria [61]. The VARS score is
the weighted sum of the presence of five visual symptom
characteristics: duration 5–60 min (3 points), develops
gradually over at least 5 min (2 points), scotoma (2
points), zig-zag lines (2 points) and unilateral (1 point)
(Table 7). A VARS score of ≥5 out of a maximum score of
10 points has a sensitivity of 96% (95% CI 92–99%) and a
specificity of 98% (95% CI 95–100%) for migraine aura.
A further available tool is represented by the LUMINA
(Leiden University MIgraine Neuro-Analysis) web-based
questionnaire [62]. The questionnaire was developed for
the specific aim of being used in epidemiological studies.
A seven-question subset of the questionnaire provided
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higher sensitivity (86% vs. 45%), slightly lower specificity
(75% vs. 95%), and similar positive predictive value (86%
vs. 88%) in assessing aura when comparing with the
ICHD-II-based algorithm. The LUMINA web-based
questionnaire allows the distinction between migraine
with and without aura with a focus on visual aura symp-
toms [62]. However, currently the LUMINA has not
been validated in clinical settings.
Statement 3: In women who are seeking hormonal
contraception, we recommend consideration of the type of
hormonal contraception taking into account their influence
on the risk of ischemic stroke as there are high risk prod-
ucts (combined oral contraceptives containing >35 μg ethi-
nylestradiol), medium risk products (combined oral
hormonal contraceptives containing ≤35 μg ethinylestra-
diol, combined contraceptive patch, and combined vaginal
ring) and no risk products (progestogen-only contraceptives
including oral pill, subdermal implant, depot-injection, and
levonorgestrel-releasing intrauterine system). 1B, Strong
recommendation, Medium quality of evidence.
Comment: The risk of ischemic stroke associated with
HC use mostly depends on the estrogen compound and is
dose dependent [22, 63]. Initially, combined oral HCs con-
tained estrogen in doses up to 150 μg of mestranol, a
prodrug of ethinylestradiol. Over years, compounds con-
taining lower estrogen doses were developed and marketed.
The most common estrogen used is ethinylestradiol, cur-
rently in doses between 15 and 35 μg.
Combined oral HCs containing high dose of estrogen
(≥50 μg) have been associated with an increased risk of
ischemic stroke [23, 26, 64]. A meta-analysis reported a
4.5-fold increase in the relative risk of ischemic stroke
(95% CI 2.2–9.5) in users of combined HCs containing
≥50 μg ethinylestradiol and of 2.8-fold (95% CI 2.0–3.9)
in users of combined HCs containing 50 μg ethinylestra-
diol [23]. A more recent meta-analysis showed a 3.3-fold
increase in the same risk in users of combined HCs con-
taining ≥50 μg ethinylestradiol (95% CI 2.5–4.3) [26]. As
HCs containing a lower estrogen dose are equally effect-
ive but safer (not only in terms of ischemic stroke risk)
[23–26, 64, 65], those compounds containing high dose
of estrogen are no longer the choice even for women
without migraine. However, there are still available for-
mulations containing 50 μg of estrogen available world-
wide, but no more formulations with >50 μg of estrogen.
Formulations that contain 50 μg estrogen account for
less than 1% of contraceptives prescription in US [63].
Combined HCs containing lower estrogen doses are
considered safer but nevertheless carry an increased risk
of ischemic stroke in women in general. A meta-analysis
reported a 2.1-fold increase in the relative risk of ische-
mic stroke (95% CI 1.6–2.8) in users of combined HCs
containing <50 μg ethinylestradiol [23]. A further meta-
analysis, limited to low-dose combined HCs, showed a
2.1-fold increase in users (95% CI 1.6–2.9) [24]. A more
recent meta-analysis showed a 1.8-fold increase in the
relative risk of ischemic stroke (95% CI, 1.6–1.9) in users
of combined HCs containing 30–40 μg ethinylestradiol
and of 1.6-fold (95% CI 1.4–1.8) in users of combined
HCs contraceptives containing 20 μg ethinylestradiol [26].
A recent observational study, on a large cohort of French
women, indicated that combined HCs with 20 μg ethiny-
lestradiol were associated with a reduced relative risk of is-
chemic stroke as compared to pills containing 30–40 μg
ethinylestradiol (adjusted RR 0.8; 95% CI 0.7–1.0) [65].
The combined HCs transdermal patch and vaginal ring
are relatively new contraceptive methods. They act by
releasing hormones into systemic circulation. An open-
label, randomized study showed that exposure to ethiny-
lestradiol is lower in those who use the ring as compared
to those who use the patch or the pill [66]. Additionally,
the ring provides lower variation in serum ethinylestra-
diol levels as compared to the patch or to the ring [66].
Because the vaginal ring and transdermal patch routes
of administration avoid hepatic first-pass metabolism,
the impact on hepatic induction of coagulation factors
might be different from users of oral formulations [67].
Safety may depend on individual absorption levels of
Table 6 The Migraine-ID™ questionnaire
Identify your migraine
Take the ID Migraine™ Quiz
These 3 ID Migraine™ questions can help you learn more about your
headaches or migraines.
During the last 3 months did you have the following with your
headaches:
• You felt nauseated or sick to your stomach? Yes No
• Light bothered you (a lot more when you didn’t have
headaches)?
Yes No
• Your headaches limited your ability to work, study, or do
what you needed to do for at least 1 day?
Yes No
If you answered “yes”to 2 or more of the ID MigraineTM questions, you
may suffer from migraines. It may help you tokeep a Migraine Diary so
you can better talk to your doctor about your symptoms.
If you answered “no” to these questions, you may not have migraine,
but you should still discuss your symptoms with your doctor.
From Lipton RB et al. Neurology 2003;61:375–382 [55]
Table 7 Visual Aura Rating Scale (VARS)
Visual symptom Risk score
Duration 5–60 min 3
Develops gradually over 5 min 2
Scotoma 2
Zigzag line (fortification) 2
Unilateral (homonymous) 1
Migraine with aura diagnosis ≥5
From Eriksen MK et al. Cephalalgia 2005;25:801–810 [61]
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ethinylestradiol but according to available evidence, the
non-oral formulations provide a comparable safety and
pharmacokinetic profile to combined oral HCs with
similar hormone formulations [42]. Limited and conflict-
ing information is available on the safety of these
methods regarding vascular events [68–76]. Two studies
examined the association between the combined HC
transdermal patch use and arterial thromboembolism
but were unable to demonstrate an increased risk; how-
ever, those studies could have been underpowered [68,
72]. A further study found a non-significant 3.2-fold in-
crease in the relative risk of ischemic stroke among users
of the combined HC transdermal patch (95% CI 0.8–
12.6) and a 2.5-fold increase in the same risk among
users of the combined HC vaginal ring (95% CI 1.4–4.4)
[74]. A further cohort study did not find an increased
risk of arterial thrombotic events (including ischemic
stroke) in women who initiated treatment with com-
bined HC transdermal patch or combined HC vaginal
ring as compared to use of low-dose (10–35 μg) et-
hinylestradiol combined contraceptive [75]. A recent
systematic review pointed out that evidence did not
demonstrate an increased risk of arterial thromboembol-
ism among women using the combined HC transdermal
patch [76]. Additional studies are needed to further clar-
ify any risk among users of non-oral combined HCs. Of
note no specific data are available regarding the safety of
those compounds in women with migraine.
Several different progestogens are available in current
combined HC formulations. Progestogens are classified
into first (norethisterone), second (norgestrel, levonoges-
trel), third (desogestrel, gestodene norgestimate), and
fourth (drospirenone) generation compounds. New gen-
eration progestogens were developed to reduce side ef-
fects having less androgenic properties. The newer
progestogens also enabled the use of low-dose estrogen
formulations. Although they have better lipid profiles
and promote less insulin resistance compared to 2nd
generation progestogens, the 3rd generation progesto-
gens failed to reduce the risk of stroke and myocardial
infarction. There is no substantial difference in the is-
chemic stroke risk among the different progestogens
contained in combined HCs [67, 77]. A meta-analysis
showed, for <50 μg ethinylestradiol pills, the relative risk
associated with first-, second-, and third generation pro-
gestogens was 2.2 (95% CI 1.1–4.3), 2.9 (95% CI 2.2–
3.8), and 2.5 (95% CI 0.8–6.2), respectively [23]. In a fur-
ther meta-analysis, the relative risk of ischemic stroke
associated with pills containing second- and third-
generation progestogens was 2.5 (95% CI 2.0–3.3) and 2.0
(95% CI 1.2–3.6), respectively [24]. A further study
showed that the risk of ischemic stroke did not differ sig-
nificantly according to the type of progestogen in users of
combined HCs containing 30–40 μg ethinylestradiol [74].
Third and 4th generations progestogens, when used in
combined formulations, may also be associated with an in-
creased risk of venous thromboembolism [78, 79]. Devel-
opment of arterial thrombosis is most likely due to
estrogen effects of combined HCs on the coagulation sys-
tem. Available data indicated that there is no increased
risk of ischemic stroke associated with progestogen-only
[18, 20, 80–86], including progestogen-only injectable
(primarily medroxyprogesterone acetate) [86], subdermal
implants [74, 84], the levonorgestrel intrauterine system
[74] and progestogen-only pills [18, 20, 74, 81, 86]. A
meta-analysis of 6 case-control studies of progestogen-
only HCs showed a pooled risk of 1.0 (95% CI 0.7–1.3)
[80]. These data were further supported by a recent
pooled analysis of data which indicated that progestogen-
only HCs were not associated with an increased risk of is-
chemic stroke (OR, 1.0; 95% CI, 0.7–1.4) [26].
Statement 4: In women with migraine with aura who
are seeking hormonal contraception, we suggest against
prescription of combined hormonal contraceptives (oral
pill, transdermal patch, and vaginal ring) containing ethiny-
lestradiol and 17β-estradiol/estradiol valerate. 2C, Weak
recommendation, Low quality of evidence.
Comment: As reported earlier in this text, combined
HCs containing low dose of ethinylestradiol, even if safer
than compounds containing higher dose, have also been
associated with an increased risk of ischemic stroke [23,
24, 26]. The relative increase in the risk of ischemic
stroke with the use of combined oral formulations con-
taining an ethinylestradiol dose between 20 and 40 μg is
about 2-fold [25, 74]. However, the absolute risk of is-
chemic stroke is small due to the low incidence of the
disease in healthy young women [37]. Although ischemic
stroke events are overall rare among women of repro-
ductive age they can have devastating complications
associated with significant morbidity and mortality. Des-
pite the overall low absolute risk of ischemic stroke from
combined HCs, certain subgroups of women, including
those with migraine with aura, may be at higher risk of
stroke. In fact, as reported in the systematic review,
some studies indicated that use of HCs in women with
migraine is associated with further increase in the risk of
ischemic stroke [17, 34]. As migraine with aura is a risk
factor for ischemic stroke [8–18] use of combined HCs
is contraindicated in women with this condition as sup-
ported also by the World Health Organization [42], the
UK Faculty of Sexual and Reproductive Healthcare [41]
and the US Centers for Disease Control and Prevention
[40]. Women are not denied effective contraception as
other methods are available. However, the Panel points
out that further studies should address the possible
threat driven by the association between HCs use in
women with migraine. In fact, most of the studies which
indicated an increased risk of ischemic stroke in women
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with migraine lacked some specific data. First of all, in
most of those studies there was no information accord-
ing to migraine subtype (i.e. with or without aura). How-
ever, this may represent a limitation mostly for migraine
without aura, which (as detailed later in this text) has
not been reliably associated with an increased risk of is-
chemic stroke. For migraine with aura, available studies
are more homogeneous in indicating an association with
increased risk of ischemic stroke. The other point of lack
of evidence refers to the dose of ethinylestradiol. Even
though estrogen dose is related to the risk of stroke in
the general female population, as described in the com-
ment to Statement 3, it remains unclear how the estro-
gen dose could impact on the risk of ischemic stroke in
women with migraine [1, 5, 11, 17, 18, 26, 33, 34]. Only
two studies provided the risk of ischemic stroke in
women with migraine according to ethinylestradiol dose
[11]. In the first study, women using <50 μg ethinylestra-
diol dose were included [34]. In this study, the relative
risk of ischemic stroke was increased by 2.1-fold in
current HCs users (95% CI, 1.2–3.7) who had migraine
but the same risk was not elevated among women with-
out such a history as compared to HCs non-users [34].
In the second study the relative risk of ischemic stroke
was increased by 16.9-fold in migraineurs who were HC
users (95% CI 2.7–106) but the study was unable to
demonstrate an association in migraineurs who were HC
non-users as compared to non-migraineurs and non-
users [11]. When analysis was stratified by estrogen dose
authors found a non-significant increase in the relative
risk of ischemic stroke in migraineurs who were users of
low (<50 μg) estrogen dose (OR 6.6; 95% CI 0.8–54.8)
whereas the risk for higher (≥50 μg) doses could not be
computed in that study [11].
Combined HCs containing estradiol, an endogenous
ovarian hormone, have been developed [67, 78] to re-
duce risk of thrombotic events associated with ethinyles-
tradiol. Pills containing micronized 17β-estradiol and
estradiol valerate are currently available on the market.
Pills containing estradiol in similar levels to the natural
hormone cycle should be in theory associated with a
relatively lower risk of ischemic stroke compared to the
synthetic ethinylestradiol. A preliminary study suggested
that the risk of venous thromboembolism with the estra-
diol valerate/dienogest was lower than with 3rd and 4th
generation combined HCs and higher than a levonorges-
trel/ethinylestradiol pill [Lidegaard O, personal communi-
cation]. In the same report, the risks for acute myocardial
infarction and thrombotic stroke appeared to be lower
with dienogest/estradiol valerate than with 2nd generation
combined HCs. Some preliminary data indicate that com-
bined HCs containing estradiol valerate are associated
with lower cardiovascular risk as compared to combined
HCs containing ethinylestradiol [87]. The International
Active Surveillance study Safety of Contraceptives: Role of
Estrogens (INAS-SCORE) was an observational study in-
vestigating the cardiovascular risks associated with the use
of a combined HCs containing dienogest and estradiol val-
erate compared to established combined HCs (mostly
containing ethinylestradiol and levonorgestrel) in a rou-
tine clinical setting in the United States and Europe [87].
The study indicated that the dienogest and estradiol
valerate pill is associated with similar or even lower car-
diovascular risk compared to levonorgestrel containing
combined HCs and other combined HCs [87]. However,
as the study follow-up was relatively short (mean
2 years) and number of events was low no firm conclu-
sions could be drawn. Additionally, no information was
available on migraine status. At the moment, there is
not enough evidence to conclude about the cardiovas-
cular safety of combined HCs containing estrogens
other than ethinylestradiol. Until such evidence will be-
come available, combined pills with natural estrogen
should be considered as other types of combined pills.
Statement 5: In women with migraine with aura who
are seeking contraception we suggest non-hormonal
contraception (condoms, copper-bearing intrauterine de-
vice, permanent methods) or progestogen-only contracep-
tives (oral pill, subdermal implant, depot-injection, and
levonorgestrel-releasing intrauterine system) as the prefer-
ential option. 1C, Strong recommendation, Low quality of
evidence.
Comment: Progestogen-only contraceptives include
progestogen-only pills, subdermal implants, and intrauter-
ine systems. Progestogen-only contraceptives are associ-
ated with more breakthrough bleeding and, in some
formulations, lower contraceptive efficacy than combined
HCs [78]. Moreover, depot preparations of medroxypro-
gesterone acetate have been linked to reversible decreases
in bone density [78]. Though there is a debate [83, 88]
about whether different progestogens impact the risk of
venous thromboembolism, progestogens do not appear to
affect the risk of arterial events [64]. In fact, the cardiovas-
cular risk associated with combined HCs, has been mainly
attributed to the estrogen component which exerts a
strong effect on the coagulation system. In two meta-
analyses, progestogen-only contraceptives have not been
associated with an increased risk of ischemic stroke [26,
80]. There are no studies that specifically tested the safety
of those compounds in women with migraine regarding
ischemic stroke risk. Only one study clearly indicated that
subjects using progestogen-only were included, but those
compounds were used by less than 5% of all women with
migraine and no results were reported according to hor-
monal contraceptive type [18]. In the absence of clear evi-
dence on the risk of ischemic stroke associated with the
use of progestogen-only contraceptives in women with
migraine, currently indirect evidence does not link the use
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of those compounds with an increased risk of arterial
events including ischemic stroke (for additional informa-
tion refer to comment to Statement 3) [76]. For those rea-
sons, there are no issues which may contraindicate their
use in subjects with migraine. Additionally, some studies
indicated that the use of progestogen-only contraceptives
in women with migraine is associated with significant re-
duction in migraine attack frequency, migraine intensity,
use of triptans and pain score and in improvement in
quality of life [89–95].
Statement 6: In women with migraine with aura who
are already using combined hormonal contraceptives for
contraception, we suggest switching to non-hormonal
contraception (condoms, copper-bearing intrauterine de-
vice, permanent methods) or progestogen-only contra-
ceptives (oral pill, subdermal implant, depot-injection,
and levonorgestrel-releasing intrauterine system). 2C,
Weak recommendation, Low quality of evidence.
Comment: No studies provided reliable clinical infor-
mation to establish whether the risk of having ischemic
stroke associated with the use of combined HCs in
women with migraine declines with long-time use. How-
ever, a clear close temporal relationship between initi-
ation of combined HCs and ischemic stroke onset has
not been identified. For this reason, use of those com-
pounds should be discontinued whenever the risk factor
migraine with aura is recognized. This suggestion is even
more stringent in those subjects who experience high
migraine attack frequency. In fact, as reported earlier in
this text some preliminary data indicate that migraine
attack frequency of women with migraine with aura ap-
pears to be an issue for determining the risk of ischemic
stroke [17, 44, 45] as the increased risk seems to be car-
ried by high migraine attack frequency rather than spor-
adic attacks.
Statement 7: In women with migraine without aura
who are seeking hormonal contraception and who have
additional risk factors (cigarette smoking, arterial hyper-
tension, obesity, previous history of cardiovascular disease,
previous history of deep vein thrombosis or pulmonary
embolism), we suggest non-hormonal contraception
(condoms, copper-bearing intrauterine device, permanent
methods) or progestogen-only contraceptives (oral pill,
subdermal implant, depot-injection, and levonorgestrel-
releasing intrauterine system) as the preferential option.
2C, Weak recommendation, Low quality of evidence.
Comment: For migraine without aura, the interpret-
ation of available data is rather complex as some studies
reported that migraine without aura is associated with
an increased risk of ischemic stroke [10, 18, 19] whereas
in others the association was not confirmed [11, 15, 16].
Further, the definition of a clear association between mi-
graine without aura and ischemic stroke is even more
complex as some studies linking migraine with ischemic
stroke risk had no information on migraine aura [2, 18, 20]
and because the challenge of migraine aura diagnosis in
population-based studies. It should also be considered that
data, which showed the increased risk of ischemic stroke in
women with migraine, mostly refer to migraine overall and
that migraine without aura accounts for most migraines.
Considering those issues, probably migraine without aura
carries some risk of ischemic stroke even if this risk is lower
than that observed in subjects with migraine with aura.
Additionally, one recent study indicated an increased risk
of ischemic stroke in women with migraine without aura
using HCs (OR 1.8; 95% CI 1.1–2.9) [10]. The risk of ische-
mic stroke in this study was also increased in women with
migraine without aura not using HCs (OR 2.2, 95% CI 1.9–
2.7). However, in this study authors did not provide the risk
of ischemic stroke in migraineurs without aura using HCs
versus not using HCs. Unless new studies will provide more
clear evidence about the risk of ischemic stroke in women
with migraine without aura using HCs, the Panel suggest to
privilege safety and methods which do not carry any in-
creased risk of ischemic stroke in women with migraine
without aura with additional risk factors. This position is in
line with the content of the medical eligibility criteria by
the World Health Organization [42], the UK Faculty of Sex-
ual and Reproductive Healthcare [41]and the US Centers
for Disease Control and Prevention [40].
Statement 8: In women with migraine without aura
who are seeking hormonal contraceptives and who have
no additional risk factors (cigarette smoking, arterial
hypertension, obesity, previous history of cardiovascular
disease, previous history of deep vein thrombosis or pul-
monary embolism) we suggest the use of combined
hormonal contraceptives containing ≤35 μg dose of ethi-
nylestradiol as a possible contraceptive option with moni-
toring of migraine frequency and characteristics. Benefits
and risk of combined hormonal contraceptives use in
comparison to other contraceptive options have to be bal-
anced carefully. 2C, Weak recommendation, Low quality
of evidence.
Comment: As combined HCs may have also non-
contraceptive benefits the Panel supports their possible
use in women with migraine without aura in the absence
of any other factor which could potentially increase the
risk of ischemic stroke. Non-contraceptive benefits of
combined HCs include prevention of cancer [96, 97].
Additionally, combined HCs may have different impact
on the course of migraine and in some cases improve-
ments may be appreciated [98, 99]. As data indicated
that migraineurs may have increased burden of some
cardiovascular risk factors as compared to non-
migraineurs, careful screening is needed [100]. In case of
use, monitoring of migraine characteristics may be rele-
vant and cessation of the compound in the presence of
worsening of frequency or severity. As data indicated
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that active rather than past migraine is associated with
increased risk of ischemic stroke as also high migraine
attack frequency [15] we suggest careful review and pos-
sibly change prescription if migraine changes towards a
worsening pattern after initiation of combined HCs.
Statement 9: In women with migraine with aura or mi-
graine without aura who require hormonal treatment for
polycystic ovary syndrome or endometriosis we suggest to
select the hormonal treatment of choice (progestogen-only
or combined hormonal contraceptives) on clinical grounds.
2C, Weak recommendation, Low quality of evidence.
Comment: In the presence of a medical condition re-
quiring hormonal treatment there is a different risk/
benefit profile. Polycystic ovary syndrome (PCOS) is a
common gynecological disorder associated with hyper-
androgenism and menstrual disorders with chronic ano-
vulation, infertility hirsutism, acne and obesity [101].
Endometriosis is characterized by the presence of
endometrial-like tissue outside the uterus and is associ-
ated with a chronic inflammatory reaction; its main
symptoms are pain and infertility. In PCOS additionally,
patients often suffer from metabolic disorders: insulin
resistance, hyperinsulinemia, dyslipidemia, leading to
atherosclerosis and other irregularities of the metabolic
syndrome. Chronic inflammation usually accompanies
also PCOS. Additionally, these patients often suffer from
metabolic disorders: insulin resistance, hyperinsulinemia,
dyslipidemia, leading to atherosclerosis and other irregu-
larities of the metabolic syndrome. Because of the meta-
bolic abnormalities observed in patients with PCOS,
they are in the high-risk group for development of car-
diovascular diseases [102–104]. Women with PCOS
should have medical care from the time of diagnosis. It
should consist not only in the treatment of hormonal
disorders and infertility, but also in early diagnosis, pre-
vention and treatment of metabolic disorders. This will
reduce the risk of cardiovascular disease and its compli-
cations in the future and improve the patient’s quality of
life. Additionally, some data suggest that HCs may have
a favorable effect on the risk of vascular diseases in
women with PCOS [105].
Statement 10: In women who start combined hormonal
contraceptives for contraception and who develop new on-
set of migraine with aura, or who develop new onset mi-
graine without aura in a temporal relationship to starting
the hormonal contraceptive, we suggest switching to non-
hormonal contraception (condoms, copper-bearing intra-
uterine device, permanent methods) or progestogen-only
contraceptives (oral pill, subdermal implant, depot-
injection, and levonorgestrel-releasing intrauterine system).
2C, Weak recommendation, Low quality of evidence.
It is well known that combined HCs may impact on
the course of migraine [106]; the impact may consist of
worsening of previous migraine, in developing de novo
migraine (with or without aura), or in some cases in im-
proving migraine. Some women do not experience any
headache change associated with the use of combined
HCs. Some women do appear to have a higher risk of
headache exacerbation or new-onset headache attribut-
able to combined HC use. This mostly occurs with the
use of combined HCs that provide a drop estrogen that
is equivalent to the end-luteal phase drop. This higher
risk is most apparent in women with a strong personal
or family history of troublesome headaches, particularly
migraine [67]. The risk also increases with age. Even
within the higher risk groups, some women note im-
provement in headache with combined HCs use. In sev-
eral women reporting initial worsening, headache
complaints decrease with continued use. It is not always
easy and obvious to establish a clear relationship be-
tween migraine onset or worsening and use of combined
HCs. In fact, migraine typically starts in teens/twenties,
so association with HCs use may be coincidental. It is
worth to consider that any change in migraine pattern is
only likely to be associated with hormone use if there
has been a clear temporal relationship. An increase in
migraine frequency several years after starting HCs is
more probably associated with independent, non-
hormonal triggers. Headache that is related to combined
HCs use generally is precipitated by estrogen withdrawal
during the pill-free or placebo pill week of treatment
and causal relationship is probably more definite when
attacks occur regularly during hormone-free interval.
Continuous treatment may ameliorate attacks occurring
in the pill-free or placebo pill interval of treatment.
There are no studies which have addressed whether
changing from migraine without aura into migraine with
aura, associated with initiation of combined HC, is asso-
ciated with an increased risk of vascular events including
ischemic stroke. However, there are some old data, from
studies of high-dose combined HCs, which suggest that
the development of migraine aura in women using those
compounds correlates with increased platelet activation
[107, 108]. The Womens’ Health Study showed that only
active migraine with aura was associated with increased
risk of ischemic stroke (OR 1.9, 95% CI: 1.2–3.1)
whereas prior migraine, more than 1 year before
entry into the study (OR 0.8; 95% CI 0.4–1.4), was
not associated with increased risk of any ischemic
event at follow up. However, there are no data re-
garding how long a women already had their migraine
prior to study entry and how changes of migraine sta-
tus during the 11.9 year follow-up affect the results
[15]. Additionally, we have also to consider that there
are no data available whether improvement of mi-
graine with HCs use, as well with any other preventa-
tive treatment, are associated with decrease the risk
of vascular events.
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Statement 11: In women with migraine with or without
aura who require emergency contraception, we suggest
the use of levonorgestrel 1.5 mg orally, ulipristal acetate
30 mg orally, or the copper-bearing intrauterine device.
2C, Weak recommendation, Low quality of evidence.
Comment: Emergency contraception, or post-coital
contraception, refers to methods of contraception that
can be used to prevent pregnancy after sexual inter-
course. There are 2 methods of hormonal emergency
contraception: progestin-only pills (levonorgestrel) and
progesterone receptor modulator pill (ulipristal acetate);
the copper-bearing intrauterine device can be also used
as non-hormonal method. There are no reliable data
that systematically addressed the risk of ischemic stroke
associated with emergency contraception. However, as
the duration of use of emergency contraceptive pills is
less than the duration of regular use of combined HCs
and they would be expected to have less clinical impact
on ischemic stroke risk in women with migraine. Some
case reports link emergency contraception to stroke oc-
currence [109–113]. However, those data do not allow
to reliably establish a causal relationship between emer-
gency contraceptive use and ischemic stroke due to the
lack of a control group. In two [109, 110] of those re-
ports the emergency contraceptive was represented by
two tablets of levonorgestrel 250 mg plus ethinylestra-
diol 50 mg 19 h before presentation and a second dose
of two tablets 7 h before presentation (e.g. a total of four
tablets and 200 mg of ethinylestradiol in a 12-h period
of time). This method has currently been superseded. In
a further report the ischemic stroke was associated with
the use of levonogerstrel 1 mg plus ethinylestradiol
0.20 mg [113]. In a fourth case report the emergency
contraceptive pill was represented by levonorgestrel
1.5 mg but the pill had been taken only once, 3 months
prior to stroke onset, and so the causal relationship ap-
pears weak [111]. The same pill was associated with is-
chemic stroke occurrence in a further report, but in this
case the pill had been taken the day before stroke onset
making more possible a causal relationship [112].
Statement 12: In women with migraine with or without
aura seeking hormonal contraception, we suggest against
specific tests (e.g. thrombophilia screening, patent for-
amen ovale evaluation or neuroimaging evaluation) to de-
cide about hormonal contraceptive prescription unless
those tests are indicated by the patient’s history or by the
presence of specific symptoms. 2C, Weak recommenda-
tion, Low quality of evidence.
Comment: Little is known about a possible risk profile
predisposing women with migraine to ischemic stroke.
Despite for most women with migraine combined HCs
are safe and highly effective methods of contraception
with added non-contraceptive health benefits some
women with migraine may experience an ischemic
stroke associated with the use of HCs. There are no reli-
able markers which may be used to select those women
with migraine in whom HC use may lead to ischemic
stroke. Prothrombotic factors may potentially increase
the risk of ischemic stroke associated with combined HC
use [114–116]. However, thrombophilia is a very rare
condition and available tools screens only identify cur-
rently known factors but others may exist for which
there is no screening yet. Most women with ischemic
stroke, associated or not with migraine and use of HC,
do not have recognized hereditary coagulation problems.
A systematic review and meta-analysis addressed the
possible benefits of thrombophilia screening for venous
thromboembolism risk in the setting of combined HC
use [117]. Authors found that despite combined HC use
was associated with an increased risk of venous
thromboembolism in patients with thrombophilia, the
benefits of screening were modest because of the low ab-
solute risk due to the low prevalence of thrombophilias.
As ischemic stroke is much less common than venous
thromboembolism [74] the yield of routine screening
would be even lower for ischemic stroke. Any possible
test would involve costs which are not sustainable unless
benefits of the screening test have been proven. Data
about the association between migraine and patent for-
amen ovale are controversial. Several studies showed an
increased prevalence of patent foramen ovale in subjects
with migraine as compared to non-migraineurs [118–
120]. The only population-based study investigating this
association found no relationship between those two
conditions but this study included mostly subjects of
non-reproductive age [121]; this was not different when
only considering migraine with aura. A meta-analysis in-
cluding case-control studies demonstrated a 2.5-fold in-
creased (95% CI 2.0–3.1) prevalence of patent foramen
ovale in patients with migraine and a 5.1-fold (95% CI
4.7–5.6) increased prevalence of migraine in patients
with patent foramen ovale [119]. The relationship be-
tween migraine with aura, ischemic stroke, and patent
foramen ovale remains not entirely clear and it is pos-
sible that it may be relevant in a subset of patients [122].
However, in the majority of patients with migraine there
is no clear involvement of patent foramen ovale in the
increased risk of ischemic stroke. Several studies have
also indicated that compared to individuals without mi-
graine, patients with migraine have a higher burden of
asymptomatic white matter brain lesions and, according
to some studies, infarct-like lesions on brain magnetic
resonance imaging [123–126]. Those lesions may sug-
gest chronic ischemic disease but their nature remains
elusive because of lack of neuropathological correlation.
However, there is insufficient evidence to suggest that
those alterations represent markers of increased stroke
risk in patients with migraine.
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Statement 13: In women with non-migraine headache
who are seeking hormonal contraception any low-dose
hormonal contraceptive can be used. 2C, Weak recom-
mendation, Low quality of evidence.
Comment: Few studies evaluated the risk of ischemic
stroke in subjects with headache other than migraine
[14, 127–131]. Currently, there is no evidence that reli-
ably indicates that non-migraine headaches are associ-
ated with an increased risk of ischemic stroke. The
association remains unknown in young women as the
available studies mostly involved older subjects. One
study, involving subjects aged ≥60 years, did not find an
association between non-migraine headache and ische-
mic stroke; however, the number of included subjects in
this study was low and it may have been underpowered
to demonstrate a significant association [129]. A second
study showed an increased risk of total stroke after 1 year
of follow-up in men with headache (HR 3.9; 95% CI 2.0–
7.8), which leveled off over the course of the remaining
follow-up but remained increased [127]. In women,
however, such an association could not be established
[127]. A further study found increased risk of stroke
among men and women who reported analgesic use for
headache in general, but the classification of headache
and stroke in this study was imprecise [128]. In addition,
data from the Women’s Health Study did not show an
increased risk of ischemic stroke in women aged ≥45
years with headache in general or non-migraine head-
ache [14]. A recent study in Asians, including subjects
aged ≥18 years, found that tension type headache was
associated with increased risk of ischemic stroke (HR
2.3; 95% CI 1.2–2.8) [131]. However, as diagnosis of ten-
sion type headache was based on using administrative
coding data only, further studies using validated diagnoses
are needed to establish a possible association between the
two conditions. Another recent study involving subjects
aged >65 years indicated that whereas subjects with mi-
graine had no increased risk of any stroke, subjects with
non-migraine headache were twice as likely to have any
stroke (HR 2.0; 95% CI 1.0–3.9) [130].
Discussion
Evidence addressing the risk of ischemic stroke associ-
ated with the use of HCs is generally poor. All informa-
tion relies on observational data [23–26, 64, 65, 68–76,
80–88, 132], which may carry the risk of potential bias.
Available studies had different settings and used differ-
ent groups for comparing risks, limiting reliable com-
parison of studies as a pooled analysis of data. Most of
the available studies were published several years ago
and used compounds which are different from those
available today. Additionally, in most studies not enough
information is available regarding the type of HCs con-
sidered and in most cases results are not provided
according to migraine type. Consequently, much efforts
are needed to further investigate the possible risk associ-
ated with the use of HCs in women with migraine. Des-
pite those limitations, available data pointed toward an
increased risk of ischemic stroke associated with the use
of HCs in women with migraine. Considering this evi-
dence, and unless studies will prove safety of the use of
combined HCs in women with migraine, the present
recommendations from this Consensus Group give pri-
ority to safety and suggest several limitations in the use
of combined HCs in women with migraine. However, ac-
cording to available evidence it cannot be excluded that
currently available combined HCs are safer than those
included in the studies reviewed, particularly the older
studies, and that future recommendations may be less
restrictive. But at present, we believe that caution is
mandatory. In fact, even if the absolute risk associated
with the use of combined HC may not be high, the con-
sequences of an ischemic stroke may be devastating for
patients and their families. There are alternative methods
which provide similar contraceptive benefits but that are
much safer in terms of risks. The present recommenda-
tions support the use of those methods as preferential
contraceptive option in women with migraine. As com-
bined HCs exert some non-contraceptives benefits such
as a protecting role against endometrial, ovarian, and
bowel cancer, future studies should consider combined
endpoints to globally address benefits and risk related to
the use of combined HCs. Previous Recommendations
about use of HC in women with migraine were published
by the International Headache Society in 2000 [133]. In
that document, the Authors did not contraindicate com-
bined HC use in the absence of migraine with aura or add-
itional risk factors for ischemic stroke. The present
document provides more details referring to type of HC
as to different situations and comorbidities even in
women with migraine without aura.
The Consensus Group considers that it is necessary to
conduct further research to identify safe HC methods
for women with migraine (i.e. evaluation of the different
doses of ethinylestradiol, of the risk associated with nat-
ural estrogens, and the risk associated with the different
progestogen formulations), to clarify mechanisms linking
HCs to increased stroke risk in women with migraine,
and to identify subgroups of migraineurs with high risk
of stroke. Future studies should assess the risk of isc-
hemic stroke in women with migraine according to
migraine subtype (i.e. with or without aura) using com-
bined HCs (including dose and type of hormones) or
progestogen-only contraceptives versus those women
with migraine not using combined HCs or progestogen-
only contraceptives. Another point of further research is
to clarify the risk of ischemic stroke associated with
combined HCs containing natural estrogens versus
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ethinylestradiol. Further data are also needed to better de-
fine the risk and benefits of non-oral combined HCs
(combined contraceptive transdermal patch and combined
vaginal ring). Additionally, basic research studies should
try to understand why combined HCs increase the risk of
ischemic stroke and the specific mechanisms leading to
the vascular events in women with migraine. Studies
should try to identify possible markers for the increased
risk of stroke in migraineurs and for the risk of developing
thrombosis associated with the use of HCs. Future studies
should also try to understand how migraine features (e.g.,
frequency or duration of the disease) may impact on the
risk of ischemic stroke associated with HC use and if there
are age groups at particularly high risk.
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